[
    {
        "file_name": "CytodynInc_20200109_10-Q_EX-10.5_11941634_EX-10.5_LicenseAgreement.txt",
        "perturbation": [
            {
                "type": "Inconsistencies - In Text Contradiction",
                "original_text": "8.2 Development and Commercial Milestone Payments. Vyera shall pay each of the following non-refundable, non-creditable payments to CytoDyn upon achievement of each of the following events with respect to the Licensed Product. Each milestone payment by Vyera pursuant to this Section 8.2 shall be payable only one time. Milestone Payment\n\nUpon [***] [***]\n\nUpon the later of (i) [***] and (ii) the [***] [***]\n\nUpon [***] [***]\n\nUpon cumulative Net Sales for the Licensed Product equal to [***] [***]\n\nUpon cumulative Net Sales for the Licensed Product equal to [***] [***]\n\nUpon cumulative Net Sales for the Licensed Product equal to [***] [***]\n\nUpon cumulative Net Sales for the Licensed Product equal to [***] [***]\n\nUpon cumulative Net Sales for the Licensed Product equal to [***] [***]\n\nUpon cumulative Net Sales for the Licensed Product equal to [***] [***]\n\nTotal [***]",
                "changed_text": "8.2 Development and Commercial Milestone Payments. Vyera shall pay each of the following non-refundable, non-creditable payments to CytoDyn upon achievement of each of the following events with respect to the Licensed Product. Each milestone payment by Vyera pursuant to this Section 8.2 shall be payable only one time, **except for the milestone payments based on cumulative Net Sales, which shall be payable each time the specified Net Sales threshold is reached**. Milestone Payment\n\nUpon [***] [***]\n\nUpon the later of (i) [***] and (ii) the [***] [***]\n\nUpon [***] [***]\n\nUpon cumulative Net Sales for the Licensed Product equal to [***] [***]\n\nUpon cumulative Net Sales for the Licensed Product equal to [***] [***]\n\nUpon cumulative Net Sales for the Licensed Product equal to [***] [***]\n\nUpon cumulative Net Sales for the Licensed Product equal to [***] [***]\n\nUpon cumulative Net Sales for the Licensed Product equal to [***] [***]\n\nUpon cumulative Net Sales for the Licensed Product equal to [***] [***]\n\nTotal [***]",
                "explanation": "This change creates an in-text contradiction. The initial statement dictates milestone payments are one-time only, but the subsequent qualification makes milestone payments tied to cumulative Net Sales recurring. This introduces uncertainty on the correct interpretation and enforcement of these payments.",
                "location": "Section 8.2"
            },
            {
                "type": "Inconsistencies - In Text Contradiction",
                "original_text": "8.8 Royalty Report; Payment. Within forty-five (45) days following the end of each Calendar Quarter after the First Commercial Sale of each Licensed Product in the Territory, Vyera shall provide CytoDyn with a report in a form reasonably acceptable to CytoDyn containing the following information for the applicable Calendar Quarter for such Licensed Product: (a) the amount of gross sales of the Licensed Product in the Territory; (b) an itemized calculation of Net Sales in the Territory showing reasonably detailed deductions; provided for in the definition of \"Net Sales\"; (c) a reasonably detailed calculation of the royalty payment due on such sales; (d) an accounting of the number of units of the Licensed Product sold; and (e) the application of the reduction, if any, made in accordance with the terms of Section 8.7. Vyera shall pay all amounts due to CytoDyn with respect to Net Sales by Vyera or its Affiliates for such Calendar Quarter at the time of the submission of such quarterly report.",
                "changed_text": "8.8 Royalty Report; Payment. Within forty-five (45) days following the end of each Calendar Quarter after the First Commercial Sale of each Licensed Product in the Territory, Vyera shall provide CytoDyn with a report in a form reasonably acceptable to CytoDyn containing the following information for the applicable Calendar Quarter for such Licensed Product: (a) the amount of gross sales of the Licensed Product in the Territory; (b) an itemized calculation of Net Sales in the Territory showing reasonably detailed deductions; provided for in the definition of \"Net Sales\"; (c) a reasonably detailed calculation of the royalty payment due on such sales; (d) an accounting of the number of units of the Licensed Product sold; and (e) the application of the reduction, if any, made in accordance with the terms of Section 8.7. Vyera shall pay **fifty percent (50%)** of all amounts due to CytoDyn with respect to Net Sales by Vyera or its Affiliates for such Calendar Quarter at the time of the submission of such quarterly report. The remaining **fifty percent (50%)** is due **one (1) year after** the submission of such quarterly report.",
                "explanation": "The original text says that payment should be at the time of report submission. The changed text specifies payment of only half at submission and the other half one year later. This creates a direct payment term conflict, inducing ambiguity and uncertainty in enforcement.",
                "location": "Section 8.8"
            },
            {
                "type": "Inconsistencies - In Text Contradiction",
                "original_text": "14.1 Notices. All notices and other communications given or made pursuant hereto shall be in writing and shall be deemed to have been duly given on the date delivered, if delivered personally, or on the next Business Day after being sent by reputable international overnight courier (with delivery tracking provided, signature required and delivery prepaid), in each case, to the Parties at the following addresses, each as may be specified below (or at such other address for a Party as shall be specified by notice given in accordance with this Section 14.1).\n\nIf to Vyera:\n\nVyera Pharmaceuticals, LLC 600 Third Avenue, 10t h Floor New York, NY 10016 Attention: Legal Department Email: [***]\n\nwith a copy to:\n\nMorgan, Lewis & Bockius LLP 101 Park Avenue New York, NY 10178-0060 Attention: [***] Email: [***]",
                "changed_text": "14.1 Notices. All notices and other communications given or made pursuant hereto shall be in writing and shall be deemed to have been duly given on the date delivered, if delivered personally, **or three (3) business days after being sent by certified mail (return receipt requested)**, or on the next Business Day after being sent by reputable international overnight courier (with delivery tracking provided, signature required and delivery prepaid), in each case, to the Parties at the following addresses, each as may be specified below (or at such other address for a Party as shall be specified by notice given in accordance with this Section 14.1).\n\nIf to Vyera:\n\nVyera Pharmaceuticals, LLC 600 Third Avenue, 10t h Floor New York, NY 10016 Attention: Legal Department Email: [***]\n\nwith a copy to:\n\nMorgan, Lewis & Bockius LLP 101 Park Avenue New York, NY 10178-0060 Attention: [***] Email: [***]",
                "explanation": "This creates an in-text contradiction by adding another method of delivery, certified mail, and a new delivery timeframe (three business days after sending). This conflicts with the original's immediate deemed delivery for personal delivery and next business day delivery for overnight courier, leading to disputes over when a notice is officially considered delivered.",
                "location": "Section 14.1"
            }
        ]
    }
]